Literature DB >> 11813240

Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35.

Niranjana D Amin1, Wayne Albers, Harish C Pant.   

Abstract

Cyclin-dependent kinase 5 (cdk5), in contrast to other members of the cyclin-dependent kinase family, is not activated by cyclins but instead is activated by complexing with neuron-specific activator molecules (p35, p39, and p67). The most effective activator of cdk5 both in vitro and in vivo is p35. We have taken a kinetic approach to study the interaction between p35, its various truncated forms, and cdk5 to understand better the mechanism of its activation. The cdk5 complexes formed with the truncated forms p25 and p21 produced similar maximum active kinase, whereas the cdk5 complexed with full-length p35 and a further truncated form spanning amino acid residues from 138 to 291, with approximate molecular weight of 16 kDa (p16), produced slightly less (80%) activation than p25. P16 was the smallest fragment of p35 that produced activation equal to or greater than that of full-length p35. By examination of further truncations of p16, we found that a small number of residues, 11 and 4 at the N- and C-termini, respectively, of p16, are essential for cdk5 activation. Further truncation, removing both essential N- and C-terminal domains, produces a peptide with markedly higher affinity for cdk5 compared with the peptides that retain either of these domains. Using these inactive truncated peptides as inhibitors, we examined the kinetics of activation. From these studies we conclude that activation involves at least three cdk5-interacting domains, one located at each end of p16 and at least one located in a central domain. The cdk5 activation process is slow: The second-order rate constant for p16 is about 1.2 microM(-1) hr(-1). On the basis of kinetic data, we suggest that cdk5 exists in two conformations. The inactive kinase conformation predominates in the absence of the activator. Activation occurs in two stages: a rapid and reversible interaction of cdk5 with its activator, which involves only one or two binding domains, followed by a slow stabilization of the active conformation as interaction with all three domains is achieved. Published 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11813240     DOI: 10.1002/jnr.10116

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  28 in total

1.  Quantum capacitance-limited MoS2 biosensors enable remote label-free enzyme measurements.

Authors:  Son T Le; Nicholas B Guros; Robert C Bruce; Antonio Cardone; Niranjana D Amin; Siyuan Zhang; Jeffery B Klauda; Harish C Pant; Curt A Richter; Arvind Balijepalli
Journal:  Nanoscale       Date:  2019-08-13       Impact factor: 7.790

2.  A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons.

Authors:  Ya-Li Zheng; Sashi Kesavapany; Maneth Gravell; Rebecca S Hamilton; Manfred Schubert; Niranjana Amin; Wayne Albers; Philip Grant; Harish C Pant
Journal:  EMBO J       Date:  2004-12-09       Impact factor: 11.598

Review 3.  Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.

Authors:  Varsha Shukla; Susan Skuntz; Harish C Pant
Journal:  Arch Med Res       Date:  2012-11-07       Impact factor: 2.235

4.  Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3.

Authors:  Bing-Sheng Li; Lei Zhang; Satoru Takahashi; Wu Ma; Howard Jaffe; Ashok B Kulkarni; Harish C Pant
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

5.  Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP.

Authors:  A Cardone; S A Hassan; R W Albers; R D Sriram; H C Pant
Journal:  J Mol Biol       Date:  2010-06-25       Impact factor: 5.469

6.  Detection and characterization of nonspecific, sparsely populated binding modes in the early stages of complexation.

Authors:  Antonio Cardone; Aaron Bornstein; Harish C Pant; Mary Brady; Ram Sriram; Sergio A Hassan
Journal:  J Comput Chem       Date:  2015-03-18       Impact factor: 3.376

7.  Overexpression of the Cdk5 inhibitory peptide in motor neurons rescue of amyotrophic lateral sclerosis phenotype in a mouse model.

Authors:  Binukumar Bk; Susan Skuntz; Michaela Prochazkova; Sashi Kesavapany; Niranjana D Amin; Varsha Shukla; Philip Grant; Ashok B Kulkarni; Harish C Pant
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

8.  Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH2-terminal kinase cascade: relevance to neurotoxic insults in Alzheimer's disease.

Authors:  Kai-Hui Sun; Hyoung-gon Lee; Mark A Smith; Kavita Shah
Journal:  Mol Biol Cell       Date:  2009-09-23       Impact factor: 4.138

9.  Cyclin-dependent kinase 5 phosphorylation of human septin SEPT5 (hCDCrel-1) modulates exocytosis.

Authors:  Niranjana D Amin; Ya-Li Zheng; Sashi Kesavapany; Jyotshnabala Kanungo; Tad Guszczynski; Ram K Sihag; Parvathi Rudrabhatla; Wayne Albers; Philip Grant; Harish C Pant
Journal:  J Neurosci       Date:  2008-04-02       Impact factor: 6.167

10.  p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity.

Authors:  Lingyan Zhang; Wen Liu; Karen K Szumlinski; John Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.